Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
me tarzan you jane
Hi Choi. Can everyone look forward to loosing 50% on this new pick within a few days like your last one???
POEFF down alot. Any reason other than more sellers than buyers???
B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, N
et Income Up 267%; 3 Year CAGR 70%; Q4 Sales Increase
B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, Net Income Up 26
7%; 3 Year CAGR 70%; Q4 Sales Increase 89% ( Marketwire )
TORONTO, ONTARIO, Mar 21, 2013 (MARKETWIRE via COMTEX) --
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a
summary of its Fiscal 2012 and Fourth Quarter (Q4) 2012 financial
results. Key highlights include:
-- Full year 2012 Sales of $5,024,154 increased 79% versus 2011
-- Revenue has grown at a compound annual growth rate of 70% over the last
three years
-- Net Income before Tax margin increased to 28% in 2012 from 15% in 2011
-- Full year 2012 Net Income after Tax of $1,541,317 increased 267%
compared to 2011
-- 2012 represented the 3rd consecutive year of profitability for the
Company
-- 2012 was the first year the Company paid income tax
-- EPS (Basic) was $0.12
-- The Company ended 2012 with $2,509,278 of working capital including
$2,316,055 of cash
-- The Company remains debt-free and has an unutilized operating line of
credit with Royal Bank of Canada
-- Selected as a TSX Venture 50 Top Performer for two consecutive years -
2012 and 2013
Total sales for Q4 2012 of $1,327,953, were 89% higher compared to
$703,337 in the corresponding prior year period. On a full year
basis, sales in 2012 of $5,024,154 were 79% higher than the previous
year sales of $2,808,666.
Net Income Before Tax for the fourth quarter of 2012 was $361,237
which is 454% higher than $65,220 in the fourth quarter of 2011. Net
Income Before Tax for full year 2012 was $1,399,122 or 233% higher
than $420,392 in corresponding prior year 2011. The Net Income before
Tax margin increased to 28% in 2012 from 15% in 2011. The Company has
chosen to use Net Income Before Tax as a key measure of performance
as it is independent of tax fluctuations that might occur due to the
utilization of carried forward loses from previous years or changes
in tax rates.
The Company has provided for an income tax liability of $90,004 for
the fourth quarter of 2012, for the first time. The Company has also
recognized a deferred tax credit for the first time - $232,199,
arising mainly from accumulated losses carried forward from previous
years while correspondingly recognizing a deferred tax asset of like
value on its consolidated statements of financial position. The full
year 2012 Net Income after Tax (NIAT) of $1,541,317 increased 267%
compared to $420,392 in 2011. Without the one-time recognition of the
deferred tax credit, Net Income after Tax for full year 2012 would
have been $1,309,118. The Total Comprehensive Income of $1,539,317
for 2012 was 268% higher than that of $417,950 in 2011. Earnings per
share (EPS) for full year 2012 were $0.12 Basic and $0.11 Diluted
compared to $0.03 Basic and $0.03 Diluted in 2011.
Working capital, which is the difference between current assets and
current liabilities, has increased by 122% from $1,128,065 as at
December 31, 2011 to $ 2,509,278 as at December 31, 2012. Cash and
cash equivalents on December 31, 2012 of $2,316,055 were 92% of
working capital compared to 94% as at December 31, 2011. Cash
Generation, or the increase in Cash and Cash Equivalents, of
$1,258,009 in 2012, represents a 114% increase over $586,951 in the
prior year period.
The Financial Statements and Management's Discussion & Analysis will
be posted on www.sedar.com on March 21, 2012. The launch of
FeraMAX(R) Powder has been delayed due to scale-up of production.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX",
BioSyent is a profitable growth oriented specialty pharmaceutical
company which searches the globe to in-license or acquire innovative
pharmaceutical products that have been successfully developed, are
safe and effective, and have a proven track record of improving the
lives of patients and supporting the healthcare professionals that
treat them.
Once a product of interest has been found, BioSyent then acquires the
exclusive rights to the product and manages it through the Canadian
governmental regulatory approval process. Once approved, BioSyent
markets the product throughout Canada.
At the date of this press release the Company had 13,271,195 shares
issued and outstanding.
B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, N
et Income Up 267%; 3 Year CAGR 70%; Q4 Sales Increase
B: BioSyent Releases Full Year 2012 Results-Sales Increase 79%, Net Income Up 26
7%; 3 Year CAGR 70%; Q4 Sales Increase 89% ( Marketwire )
TORONTO, ONTARIO, Mar 21, 2013 (MARKETWIRE via COMTEX) --
BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) released today a
summary of its Fiscal 2012 and Fourth Quarter (Q4) 2012 financial
results. Key highlights include:
-- Full year 2012 Sales of $5,024,154 increased 79% versus 2011
-- Revenue has grown at a compound annual growth rate of 70% over the last
three years
-- Net Income before Tax margin increased to 28% in 2012 from 15% in 2011
-- Full year 2012 Net Income after Tax of $1,541,317 increased 267%
compared to 2011
-- 2012 represented the 3rd consecutive year of profitability for the
Company
-- 2012 was the first year the Company paid income tax
-- EPS (Basic) was $0.12
-- The Company ended 2012 with $2,509,278 of working capital including
$2,316,055 of cash
-- The Company remains debt-free and has an unutilized operating line of
credit with Royal Bank of Canada
-- Selected as a TSX Venture 50 Top Performer for two consecutive years -
2012 and 2013
Total sales for Q4 2012 of $1,327,953, were 89% higher compared to
$703,337 in the corresponding prior year period. On a full year
basis, sales in 2012 of $5,024,154 were 79% higher than the previous
year sales of $2,808,666.
Net Income Before Tax for the fourth quarter of 2012 was $361,237
which is 454% higher than $65,220 in the fourth quarter of 2011. Net
Income Before Tax for full year 2012 was $1,399,122 or 233% higher
than $420,392 in corresponding prior year 2011. The Net Income before
Tax margin increased to 28% in 2012 from 15% in 2011. The Company has
chosen to use Net Income Before Tax as a key measure of performance
as it is independent of tax fluctuations that might occur due to the
utilization of carried forward loses from previous years or changes
in tax rates.
The Company has provided for an income tax liability of $90,004 for
the fourth quarter of 2012, for the first time. The Company has also
recognized a deferred tax credit for the first time - $232,199,
arising mainly from accumulated losses carried forward from previous
years while correspondingly recognizing a deferred tax asset of like
value on its consolidated statements of financial position. The full
year 2012 Net Income after Tax (NIAT) of $1,541,317 increased 267%
compared to $420,392 in 2011. Without the one-time recognition of the
deferred tax credit, Net Income after Tax for full year 2012 would
have been $1,309,118. The Total Comprehensive Income of $1,539,317
for 2012 was 268% higher than that of $417,950 in 2011. Earnings per
share (EPS) for full year 2012 were $0.12 Basic and $0.11 Diluted
compared to $0.03 Basic and $0.03 Diluted in 2011.
Working capital, which is the difference between current assets and
current liabilities, has increased by 122% from $1,128,065 as at
December 31, 2011 to $ 2,509,278 as at December 31, 2012. Cash and
cash equivalents on December 31, 2012 of $2,316,055 were 92% of
working capital compared to 94% as at December 31, 2011. Cash
Generation, or the increase in Cash and Cash Equivalents, of
$1,258,009 in 2012, represents a 114% increase over $586,951 in the
prior year period.
The Financial Statements and Management's Discussion & Analysis will
be posted on www.sedar.com on March 21, 2012. The launch of
FeraMAX(R) Powder has been delayed due to scale-up of production.
For a direct market quote (15 minutes delay) for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX",
BioSyent is a profitable growth oriented specialty pharmaceutical
company which searches the globe to in-license or acquire innovative
pharmaceutical products that have been successfully developed, are
safe and effective, and have a proven track record of improving the
lives of patients and supporting the healthcare professionals that
treat them.
Once a product of interest has been found, BioSyent then acquires the
exclusive rights to the product and manages it through the Canadian
governmental regulatory approval process. Once approved, BioSyent
markets the product throughout Canada.
At the date of this press release the Company had 13,271,195 shares
issued and outstanding.
Ex dividend today for another 5 cents per share. Thats 25 cents in dividends they have paid out since the summer.
Choi you sure created liquidity for a bunch of people to sell a bunch of stock this week.
Choi you never had a large position here but have been telling everyone to load up for days?
Choi I think you got bagged again.
AUNFF I guess I just voted no by selling my 20,000 shares.
Looks like gold stocks bottomed today after a death spiral for weeks. Long $AAU $NSU $MUX $PVG $PTQMF $PVG $OCANF $AUNFF
We need some paint today. Any of you guys live near a Sherwin Williams store?
MMT/MAUXF Looks like the selling over the last week has been exhausted. Can we go to new all time highs here?
I can understand your aversion to miners. Bad two years and alot of things that seem to go wrong with individual companies. You may be smart to stay out of the sector.
I have a portion in miners that I think are way undervalued. Hopefully we both make some green going forward.
Tiesto I am with you to an extent. I have a much bigger position in oils than in metals for the last few years and have had big winners. I mean MMT/MAUXF bought a slug at 17 cents a few years back. It is now $2 and has paid 20 cents in dividends. This beats the hell out any miners the last few but remember right about the time you write the miners off which would be now we probably get a couple years of over performance.
By the way I am about 7% below my all time high which can be directly blamed on my miners but if you go back 2-10 years before I was hitting all time highs because of the miners.
I have been in the miners for more than 10 years. Sometimes with a large position sometimes small. I have made allot of money in them although I will admit it is frustrating for long periods of time like now.
Geez sure looks like a low risk buying opportunity in AAU, AUNFF, PVG, OCANF, MUX, PTQMF.
Correct me if you think I am wrong.
I am in this for the long term payoff so yes short term stock performance would be nice but really doesnt make much difference when everything is said and done.
Give me a 10 bagger a few years down the road and I am as good as gold. Ha Ha
PVG Just bought some PVG. Can you say cheap.
INVESTOR20501 hey ive got an idea for you SELL YOUR SHARES
INA.V/ IONAF
ALL good news.
INA.V/ IONAF
Geez hope it is good news since I just bought the stock yesterday.
Same game different day. Knock it down first thing in the morning to scare out a few shares than move it up. Today they scared out a few and keep moving up the bid and are not getting a share. This puppy is strong.
GTGP is it real or a fraud?
MAUXF Some big trades going off in MAUXF also over 200K shares already.
Isnt GTGP a disaster?
MMT.V / MAUXF Big seller at $1.99 or market maker(s) building a short position.
I managed to accumulate around 175,000 shares over the last 6 months with my last buy taking the .06s about 10 days ago.
I actually hope this doesnt move anymore until AIVI starts taking steps in the USA.
JAG Did you see any reason why it was up so much other than more buyers than sellers?
Why is it taking so long to get a contract?
I started buying awhile back and periodically buy more. I need to go ask my Mom if I can buy more.
Boys that was me today. I put an order to buy 25,000 shares at the open. Got 20,200 to add to my stash and the price went up. Everything hinges on the company which seems to be doing great coming back from the dead here in the USA. They have said they are going to do it. Im waiting for their first move.
Maybe that constant 65,000 share seller is gone.
I bought the .06s. Just the usual circle jerk around here.
MMT.V/MAUXF I remember seeing a month or two ago where some pipe and equipment had already been ordered for the new pipeline which has not been formally been signed by Shell yet. Anybody know if they may have started working on the pipeline?
MMT/MAUXF Got my dividend yesterday and getting more dividends today in the form of capital gains. ARGGHHH Matee take the woman below.
Own a bunch of PTQMF and like the risk reward.
Kaiser im sure your dividend will show up today. They don't want to mess with you. They've seen what you are capable of when you get mad. Im surprised they never made a sequel to your first picture.
Good article gje2. You never know who might read it.
MMT/MAUXF Nice action today. I think people are looking at share price and realizing how cheap it is based on the coming events.